Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03477500 (ClinicalTrials.gov)	March 21, 2018	13/2/2018	RCT Comparing Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab in MS	Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for Patients With Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Cyclophosphamide and ATG;Drug: Alemtuzumab;Drug: Cladribine Pill;Drug: Ocrelizumab	Haukeland University Hospital	NULL	Recruiting	18 Years	50 Years	All	100	Phase 3	Denmark;Netherlands;Norway;Sweden
2	NCT00040482 (ClinicalTrials.gov)	April 1999	26/6/2002	High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis	Intensive Immunosuppression Followed by Rescue With CD34 Selected, T Cell Depleted, Leukopheresis Products in Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: Cyclophosphamide;Drug: ATG;Drug: MESNA;Procedure: Radiation therapy	Baylor College of Medicine	The Methodist Hospital System;Center for Cell and Gene Therapy, Baylor College of Medicine	Completed	18 Years	60 Years	All	10	Phase 2	United States